AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22439781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (TGC) 100 mg followed by 50 mg q 12 h
Number of subjects: 387
Study 22439781 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus Metronidazole (CTX/MET) 2 g qd plus 1-2 g daily
Number of subjects: 387
Study 22439781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (TGC)
Number of subjects: 387
Study 22439781 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone plus Metronidazole (CTX/MET)
Number of subjects: 387
Study 20733444 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 international units oxytocin diluted with 26 mL saline
Number of subjects: 412
Study 20733444 — intervention group
Group type: COMPARATOR
Intervention: 30 mL saline (placebo)
Number of subjects: 412
Study 18054289 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-intervention period (two years prior to intervention)
Number of subjects: 0
Study 18054289 — intervention group
Group type: COMPARATOR
Intervention: Study arms of the Connecticut Collaboration for Falls Prevention
Number of subjects: 0
Study 16983909 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Chinese and Western medicine (ICWM) protocol
Number of subjects: 404
Study 16983909 — intervention group
Group type: COMPARATOR
Intervention: Western medicine plus placebo
Number of subjects: 404
Study 12534515 — intervention group
Group type: EXPERIMENTAL
Intervention: 585‐nm pulsed dye laser (PDL) treatment on one scar half
Number of subjects: 11
Study 12534515 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment on the other scar half)
Number of subjects: 11
Study 12534515 — intervention group
Group type: EXPERIMENTAL
Intervention: 585‐nm pulsed dye laser (PDL) treatment
Number of subjects: 11
Study 12534515 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 11
Study 12521468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-colposcopy group session led by a trained colposcopy nurse
Number of subjects: 147
Study 12521468 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 147
Study 9599825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Cradle
Number of subjects: 90
Study 9599825 — intervention group
Group type: COMPARATOR
Intervention: Current stabilization practices
Number of subjects: 90
Study 9599825 — intervention group
Group type: COMPARATOR
Intervention: Pron Pillo and current stabilization practices
Number of subjects: 90
Study 7921756 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysprosium‐165 Hydroxide Macroaggregate (165Dy)
Number of subjects: 59
Study 7921756 — intervention group
Group type: COMPARATOR
Intervention: Yttrium‐90 Silicate (90Y)
Number of subjects: 59
Study 2971274 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative free ipratropium bromide nebuliser solution
Number of subjects: 30
Study 2971274 — intervention group
Group type: COMPARATOR
Intervention: Atrovent nebuliser solution
Number of subjects: 30
Study 31451362 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental sex education program (practical booklet and booster session)
Number of subjects: 153
Study 31451362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 153
Study 31325152 — intervention group
Group type: EXPERIMENTAL
Intervention: MPT (melphalan, prednisolone, thalidomide)
Number of subjects: 103
Study 31325152 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan, prednisolone)
Number of subjects: 103
Study 28404008 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (resection)
Number of subjects: 109
Study 28404008 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 109
Study 28404008 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 109
Study 26546405 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg orally disintegrating tablet (ODT) without water
Number of subjects: 39
Study 26546405 — intervention group
Group type: COMPARATOR
Intervention: Conventional aripiprazole 15 mg standard tablet with 240 mL water
Number of subjects: 39
Study 23501053 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 23501053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23501053 — intervention group
Group type: COMPARATOR
Intervention: Non-violent control task
Number of subjects: 0
Study 21802823 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA therapy suspended 7 days before tooth extraction (group S)
Number of subjects: 63
Study 21802823 — intervention group
Group type: COMPARATOR
Intervention: ASA therapy unaltered (group NS)
Number of subjects: 63
Study 21802823 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA therapy suspended (group S)
Number of subjects: 63
Study 19381991 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated margarine
Number of subjects: 121
Study 19381991 — intervention group
Group type: COMPARATOR
Intervention: Butter (saturated group)
Number of subjects: 121
Study 16936457 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy combined with intravenous edaravone administration for 7 days
Number of subjects: 38
Study 16936457 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 38
Study 15502927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin
Number of subjects: 20
Study 15502927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11401940 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1200 mg/d
Number of subjects: 2531
Study 11401940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2531
Study 11327443 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose didanosine
Number of subjects: 2411
Study 11327443 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 2411
Study 11327443 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 2411
Study 8217757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (5 mg/kg/day)
Number of subjects: 33
Study 8217757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8217757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 33
Study 3104249 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus Misonidazole (MISO) (400 mg/m2 daily 2 to 4 hours prior to radiation therapy)
Number of subjects: 119
Study 3104249 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone (4600 cGy pelvis plus 1000 cGy parametrial boost)
Number of subjects: 119
Study 30375013 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupressure
Number of subjects: 32
Study 30375013 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 32
Study 28641680 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated resistance and aerobic training (iRAT) during HDTBR
Number of subjects: 15
Study 28641680 — intervention group
Group type: COMPARATOR
Intervention: No exercise during HDTBR (Control)
Number of subjects: 15
Study 25923150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac 75 mg and sublingual methylcobalamin
Number of subjects: 100
Study 25923150 — intervention group
Group type: COMPARATOR
Intervention: Sublingual piroxicam 40 mg and intramuscular distilled water
Number of subjects: 100
Study 24308190 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention combined with hyperbaric oxygen therapy
Number of subjects: 62
Study 24308190 — intervention group
Group type: COMPARATOR
Intervention: Control group (hyperbaric oxygen therapy only)
Number of subjects: 62
Study 21619382 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 53
Study 21619382 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 53
Study 21619382 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 53
Study 19299519 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered interventions
Number of subjects: 9
Study 16797249 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 10 mg
Number of subjects: 207
Study 16797249 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 25 mg
Number of subjects: 207
Study 16797249 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 35 mg
Number of subjects: 207
Study 16797249 — intervention group
Group type: EXPERIMENTAL
Intervention: Onercept 50 mg
Number of subjects: 207
Study 16797249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 12878450 — intervention group
Group type: EXPERIMENTAL
Intervention: Head cooling combined with minimal hypothermia (rectal temperature 36.5-36 degrees C) for 72 hours
Number of subjects: 21
Study 12878450 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Group 1a)
Number of subjects: 21
Study 12878450 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 21
Study 12878450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling group (Group 1b) after 36 hours
Number of subjects: 21
Study 11127623 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological debriefing
Number of subjects: 0
Study 11127623 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 9583651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette brand switching
Number of subjects: 11966
Study 9583651 — intervention group
Group type: EXPERIMENTAL
Intervention: Company switching
Number of subjects: 11966
Study 9583651 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-selling premium brands (Marlboro, Camel, Newport)
Number of subjects: 11966
Study 9583651 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual unit sales for Marlboro and Camel
Number of subjects: 11966
Study 9583651 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium brand cigarettes
Number of subjects: 11966
Study 8416666 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g fish oil/d (50% n‐3 fatty acids)
Number of subjects: 18
Study 8416666 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g fish oil/d (50% n‐3 fatty acids)
Number of subjects: 18
Study 8416666 — intervention group
Group type: COMPARATOR
Intervention: Olive oil placebo
Number of subjects: 18
Study 3484505 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine intervention (specifics not provided)
Number of subjects: 287
Study 3484505 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 287
Study 29446209 — intervention group
Group type: EXPERIMENTAL
Intervention: iChoose Kidney decision aid
Number of subjects: 443
Study 29446209 — intervention group
Group type: COMPARATOR
Intervention: Standard transplantation education (control)
Number of subjects: 443
Study 27014935 — intervention group
Group type: COMPARATOR
Intervention: PFMT with EMG biofeedback and sham NMES
Number of subjects: 30
Study 27014935 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT with EMG biofeedback and intravaginal NMES
Number of subjects: 30
Study 27014935 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT with EMG biofeedback and TTNS
Number of subjects: 30
Study 24528987 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic clipping (TC)
Number of subjects: 100
Study 24528987 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter occlusion (TO)
Number of subjects: 100
Study 24601188 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 300
Study 24601188 — intervention group
Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 300
Study 24601188 — intervention group
Group type: COMPARATOR
Intervention: Dry care
Number of subjects: 300
Study 24601188 — intervention group
Group type: COMPARATOR
Intervention: All groups (Ethanol, Human milk, Dry care)
Number of subjects: 300
Study 20862711 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 34
Study 17341882 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe infusion (Iscador)
Number of subjects: 62
Study 17341882 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 62
Study 15487766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 microg/day of selenized yeast
Number of subjects: 24
Study 15487766 — intervention group
Group type: EXPERIMENTAL
Intervention: 3200 microg/day of selenized yeast
Number of subjects: 24
Study 11903959 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD1 activity in patients with Down's syndrome
Number of subjects: 35
Study 11903959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruloplasmin and copper levels in patients with Down's syndrome
Number of subjects: 35
Study 11903959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruloplasmin activities in patients with Down's syndrome
Number of subjects: 35
Study 11903959 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD1 activity in patients aged 40 years or older
Number of subjects: 35
Study 11903959 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific oxidative activity in patients aged 40 years or older
Number of subjects: 35
Study 11903959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruloplasmin oxidative activity in patients aged 40 years or older
Number of subjects: 35
Study 11903959 — intervention group
Group type: COMPARATOR
Intervention: Ceruloplasmin and copper levels in controls
Number of subjects: 35
Study 11903959 — intervention group
Group type: COMPARATOR
Intervention: SOD1 activity in controls
Number of subjects: 35
Study 9815869 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 23
Study 9815869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7886867 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact transscleral Nd: YAG cyclophotocoagulation
Number of subjects: 500
Study 7886867 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated procedures
Number of subjects: 500
Study 3220614 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg or 75 mg)
Number of subjects: 10
Study 3220614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31820121 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (35 mg) with cholecalciferol (5600 IU)
Number of subjects: 841
Study 31820121 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (35 mg) alone
Number of subjects: 841
Study 30365821 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 2 min at 30% of the maximal voluntary contraction (S30%)
Number of subjects: 12
Study 30365821 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 2 min at 50% of the maximal voluntary contraction (S50%2min)
Number of subjects: 12
Study 30365821 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 3 min at 30% of the maximal voluntary contraction (S30%3min)
Number of subjects: 12
Study 30365821 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 12
Study 26930498 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 20
Study 26930498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24280999 — intervention group
Group type: EXPERIMENTAL
Intervention: NUCAI (nurse counselling and after intervention)
Number of subjects: 205
Study 24280999 — intervention group
Group type: EXPERIMENTAL
Intervention: NUCAI
Number of subjects: 205
Study 24280999 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study 22155532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex+Ca+ (exercise with calcium supplementation)
Number of subjects: 54
Study 22155532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex+Ca- (exercise without calcium supplementation)
Number of subjects: 54
Study 22155532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-Ca+ (non-exercise with calcium supplementation)
Number of subjects: 54
Study 22155532 — intervention group
Group type: COMPARATOR
Intervention: Ex-Ca- (non-exercise without calcium supplementation)
Number of subjects: 54
Study 20712737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebbinghaus illusion context sensitivity in adults
Number of subjects: 0
Study 20712737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebbinghaus illusion context sensitivity in children
Number of subjects: 0
Study 20712737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebbinghaus illusion context sensitivity in children aged 10 years
Number of subjects: 0
Study 20712737 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebbinghaus illusion in autism
Number of subjects: 0
Study 17550040 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied vitamin 'E' (100 mg twice daily)
Number of subjects: 80
Study 17550040 — intervention group
Group type: COMPARATOR
Intervention: Systemically administered vitamin 'E'
Number of subjects: 80
Study 15970639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal rinsing with hypertonic saline (3 times daily for 7 weeks)
Number of subjects: 44
Study 15970639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal rinsing with hypertonic saline
Number of subjects: 44
Study 15970639 — intervention group
Group type: COMPARATOR
Intervention: No nasal irrigation (control)
Number of subjects: 44
Study 12453080 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and treadmill training (group A)
Number of subjects: 28
Study 12453080 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training only (group B)
Number of subjects: 28
Study 10073976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 148
Study 10073976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive use with factor II:A20210
Number of subjects: 148
Study 10073976 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive use with factor V:A1691
Number of subjects: 148
Study 10073976 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor II:A20210
Number of subjects: 148
Study 10073976 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V:A1691
Number of subjects: 148
Study 10073976 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 148
Study 7866978 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 8
Study 7866978 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8
Study 1959365 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (7 mg in 14 mL of sterile saline)
Number of subjects: 20
Study 1959365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 14 mL)
Number of subjects: 20
Study 7176840 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 484
Study 29741284 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of the 3‐year Strontium Ranelate Efficacy in Knee Osteoarthritis trial (SEKOIA)
Number of subjects: 559
Study 28378356 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed Nigella sativa seed powder (2 g/day in divided doses)
Number of subjects: 110
Study 28378356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 25661189 — intervention group
Group type: EXPERIMENTAL
Intervention: PAL1
Number of subjects: 0
Study 25661189 — intervention group
Group type: EXPERIMENTAL
Intervention: PAL2
Number of subjects: 0
Study 25661189 — intervention group
Group type: COMPARATOR
Intervention: REF
Number of subjects: 0
Study 23842758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 78
Study 23842758 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile perfusion (NP)
Number of subjects: 78
Study 23842758 — intervention group
Group type: EXPERIMENTAL
Intervention: QUADROX-i oxygenator with external arterial filter under PP
Number of subjects: 78
Study 23842758 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPIOX-FX25 and SYNTHESIS oxygenators
Number of subjects: 78
Study 20605696 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea beverage (4 cups/d)
Number of subjects: 35
Study 20605696 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (2 capsules and 4 cups water/d)
Number of subjects: 35
Study 20605696 — intervention group
Group type: COMPARATOR
Intervention: No treatment (4 cups water/d)
Number of subjects: 35
Study 19563059 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (three coagulation points per ovary)
Number of subjects: 56
Study 19563059 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (four to five coagulation points per ovary)
Number of subjects: 56
Study 19563059 — intervention group
Group type: COMPARATOR
Intervention: Group A (one coagulation point per ovary)
Number of subjects: 56
Study 19563059 — intervention group
Group type: COMPARATOR
Intervention: Group B (two coagulation points per ovary)
Number of subjects: 56
Study 17692724 — intervention group
Group type: EXPERIMENTAL
Intervention: Garenoxacin (oral or intravenous) 50-1200 mg/d for 1 to 28 days
Number of subjects: 224
Study 17692724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 15453552 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 61
Study 15453552 — intervention group
Group type: COMPARATOR
Intervention: Control oral appliance
Number of subjects: 61
Study 11816915 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with verteporfin
Number of subjects: 600
Study 9802141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg o.d.
Number of subjects: 0
Study 9802141 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7543352 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of rhGM‐CSF, 250 micrograms/m2/day (trial 1)
Number of subjects: 70
Study 7543352 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of rhGM‐CSF, 250 micrograms/m2/day (trial 2)
Number of subjects: 70
Study 7543352 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 70
Study 2083956 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuhaler (conical spacer with inhalation valve)
Number of subjects: 20
Study 2083956 — intervention group
Group type: COMPARATOR
Intervention: Tube spacer
Number of subjects: 20